Brokerages Set Albireo Pharma Inc (ALBO) Target Price at $63.75

Albireo Pharma Inc (NASDAQ:ALBO) has earned a consensus rating of “Buy” from the eight analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $65.25.

Several research analysts have weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Albireo Pharma in a research note on Friday, April 20th. They issued a “buy” rating and a $50.00 price objective on the stock. Zacks Investment Research upgraded shares of Albireo Pharma from a “sell” rating to a “hold” rating in a research note on Friday, March 30th. BidaskClub lowered shares of Albireo Pharma from a “buy” rating to a “hold” rating in a research note on Thursday, February 22nd. Wedbush reiterated an “outperform” rating and issued a $63.00 price objective on shares of Albireo Pharma in a research note on Wednesday, March 28th. Finally, Needham & Company LLC assumed coverage on shares of Albireo Pharma in a research note on Thursday, March 15th. They issued a “buy” rating and a $50.00 price objective on the stock.

In other Albireo Pharma news, COO Jan Mattsson sold 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 13th. The shares were sold at an average price of $32.26, for a total value of $806,500.00. Following the transaction, the chief operating officer now owns 43,538 shares in the company, valued at approximately $1,404,535.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 3.60% of the stock is currently owned by corporate insiders.



Several institutional investors and hedge funds have recently made changes to their positions in ALBO. Wells Fargo & Company MN increased its stake in shares of Albireo Pharma by 282.1% during the 4th quarter. Wells Fargo & Company MN now owns 6,350 shares of the biopharmaceutical company’s stock worth $162,000 after purchasing an additional 4,688 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Albireo Pharma during the 4th quarter worth $216,000. Artal Group S.A. acquired a new position in shares of Albireo Pharma during the 4th quarter worth $7,680,000. Sectoral Asset Management Inc increased its stake in shares of Albireo Pharma by 53.6% during the 4th quarter. Sectoral Asset Management Inc now owns 242,803 shares of the biopharmaceutical company’s stock worth $6,216,000 after purchasing an additional 84,776 shares during the last quarter. Finally, Perceptive Advisors LLC increased its stake in shares of Albireo Pharma by 56.2% during the 4th quarter. Perceptive Advisors LLC now owns 1,320,000 shares of the biopharmaceutical company’s stock worth $33,792,000 after purchasing an additional 475,000 shares during the last quarter. Institutional investors own 54.77% of the company’s stock.

Shares of NASDAQ:ALBO traded up $0.16 during mid-day trading on Tuesday, hitting $32.53. The stock had a trading volume of 170,055 shares, compared to its average volume of 64,101. The company has a market cap of $388.47 million, a PE ratio of -10.33 and a beta of 1.47. Albireo Pharma has a 12-month low of $15.31 and a 12-month high of $39.87.

Albireo Pharma (NASDAQ:ALBO) last issued its quarterly earnings results on Thursday, May 17th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.75 by ($3.90). The company had revenue of $11.20 million for the quarter, compared to analyst estimates of $55.33 million. sell-side analysts predict that Albireo Pharma will post -3.13 EPS for the current year.

About Albireo Pharma

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Analyst Recommendations for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply